What you should know
dRTA Communities and Resources
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephroloy. Our lead drug candidate, ADV7103, is in late-stage clinical trials for primary distal renal tubular acidosis (dRTA). Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Paris, France.
You are not alone. Connect with other members of the dRTA community on social media and with organizations providing education and support.
ADV7103 is an investigational product and has not been demonstrated to be safe and effective in the US population.